Protein-Ligand-Based Pharmacophores: Generation and Utility Assessment in Computational Ligand Profiling
暂无分享,去创建一个
Didier Rognan | Jiabo Li | Jon M. Sutter | Hugues-Olivier Bertrand | Jamel Meslamani | Adrian Stevens | D. Rognan | J. Sutter | H. Bertrand | A. Stevens | Jamel Meslamani | Jiabo Li
[1] Ajay N. Jain,et al. Chemical structural novelty: on-targets and off-targets. , 2011, Journal of medicinal chemistry.
[2] Richard A. Lewis,et al. Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.
[3] Wolfgang Guba,et al. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. , 2007, Journal of medicinal chemistry.
[4] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[5] Didier Rognan,et al. Binding of Protein Kinase Inhibitors to Synapsin I Inferred from Pair-Wise Binding Site Similarity Measurements , 2010, PloS one.
[6] Gerhard Klebe,et al. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state. , 2007, Journal of molecular biology.
[7] Didier Rognan,et al. sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins , 2011, Bioinform..
[8] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[9] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[10] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[11] Jiabo Li,et al. New features that improve the pharmacophore tools from Accelrys. , 2011, Current computer-aided drug design.
[12] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[13] Steven J. M. Jones,et al. A Computational Approach to Finding Novel Targets for Existing Drugs , 2011, PLoS Comput. Biol..
[14] Lei Xie,et al. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments , 2008, Proceedings of the National Academy of Sciences.
[15] D. Rognan. Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.
[16] Richard D. Smith,et al. CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions , 2011, J. Chem. Inf. Model..
[17] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[18] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[19] Klaus R. Liedl,et al. One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..
[20] Michael J. Keiser,et al. Off-target networks derived from ligand set similarity. , 2009, Methods in molecular biology.
[21] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..
[22] Sean Ekins,et al. When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? , 2010, Drug discovery today.
[23] E. Kellenberger,et al. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.
[24] Fedor N. Novikov,et al. CSAR Scoring Challenge Reveals the Need for New Concepts in Estimating Protein-Ligand Binding Affinity , 2011, J. Chem. Inf. Model..
[25] David Vidal,et al. Ligand-based approaches to in silico pharmacology. , 2011, Methods in molecular biology.
[26] Paul N. Mortenson,et al. Diverse, high-quality test set for the validation of protein-ligand docking performance. , 2007, Journal of medicinal chemistry.
[27] Thierry Langer,et al. Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models , 2007, J. Chem. Inf. Model..
[28] Didier Rognan,et al. Structure‐Based Approaches to Target Fishing and Ligand Profiling , 2010, Molecular informatics.
[29] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[30] Istvan J. Enyedy,et al. Can we use docking and scoring for hit-to-lead optimization? , 2008, J. Comput. Aided Mol. Des..
[31] Didier Rognan,et al. In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.
[32] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[33] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[34] Lin He,et al. Harvesting Candidate Genes Responsible for Serious Adverse Drug Reactions from a Chemical-Protein Interactome , 2009, PLoS Comput. Biol..
[35] Didier Rognan,et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.
[36] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[37] Thierry Langer,et al. Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..
[38] Thomas Stützle,et al. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..
[39] D. J. Price,et al. Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.
[40] Ajay N. Jain. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..
[41] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[42] Hong Liu,et al. Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation , 2011, J. Chem. Inf. Model..
[43] Lin He,et al. Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..
[44] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[45] Thierry Langer,et al. In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.
[46] Nathanael Weill,et al. Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..
[47] Philip E. Bourne,et al. A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology , 2010, PLoS Comput. Biol..
[48] Kai Huang,et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..
[49] Thierry Langer,et al. Pharmacophore modeling and parallel screening for PPAR ligands , 2007, J. Comput. Aided Mol. Des..
[50] Anton J. Hopfinger,et al. Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..
[51] Xin Chen,et al. The interprotein scoring noises in glide docking scores , 2012, Proteins.
[52] Thierry Langer,et al. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.